CNS Tumor Classification and Molecular Profiling

The classification of central nervous system (CNS) tumours has undergone a paradigm shift from exclusively histopathological assessment to an integrated framework that incorporates molecular characteristics alongside morphological features. The current WHO framework stratifies tumours by combining microscopic appearance, tumour grade and key genomic alterations to refine diagnostic precision, prognostic evaluation and therapeutic decision-making. Hallmark molecular markers such as isocitrate dehydrogenase (IDH) mutations, 1p/19q codeletions and histone H3 K27M alterations have been established as defining criteria for distinct entities. High-throughput approaches—next-generation sequencing, DNA methylation profiling and transcriptomic analyses—have revealed subgroups with distinct biological behaviour and treatment sensitivity. Epigenetic signatures, such as MGMT promoter methylation and CpG island methylator phenotypes, inform chemotherapeutic responsiveness, while emerging immunogenomic data highlight novel targets for immune modulation. Together, these advances have fostered a globally harmonised, layer-based diagnostic model in which each tumour receives an integrated diagnosis detailing histology, grade and requisite molecular information. This evolution underpins personalised management strategies and fuels translational efforts towards targeted agents and predictive biomarkers in neuro-oncology.

Research from Nature Portfolio

No recent Nature Portfolio content available.

CNS Tumor Classification and Molecular Profiling publication trend

The graph below shows the total number of articles in cns tumor classification and molecular profiling across all publications each year (not limited to Nature Index journals).

Technical terms

Integrated diagnosis: A diagnostic statement combining histological classification, WHO tumour grade and relevant molecular findings.

IDH mutation: Change in isocitrate dehydrogenase genes, commonly IDH1 or IDH2, associated with altered tumour metabolism and prognostic significance.

1p/19q codeletion: Simultaneous loss of chromosomal arms 1p and 19q, characteristic of oligodendrogliomas and predictive of chemosensitivity.

DNA methylation profiling: Genome-wide assessment of cytosine methylation patterns, used to classify tumours and predict therapeutic response.

Histone modification: Post-translational alteration of histone proteins (e.g. methylation, acetylation) that regulates chromatin structure and gene expression.

Next-generation sequencing (NGS): High-throughput DNA sequencing technology enabling comprehensive detection of genetic alterations.

CpG island methylator phenotype (CIMP): Widespread hypermethylation of CpG-rich genomic regions, defining a distinct epigenetic subgroup with clinical implications.

References

1. Signaling pathways in brain tumors and therapeutic interventions. Signal Transduction and Targeted Therapy (2023).
2. DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets. Cancers (2023).
3. The WHO 2021 Classification of Central Nervous System tumours: a practical update on what neurosurgeons need to know—a minireview. Acta Neurochirurgica (2022).
4. Reclassification of TCGA Diffuse Glioma Profiles Linked to Transcriptomic, Epigenetic, Genomic and Clinical Data, According to the 2021 WHO CNS Tumor Classification. International Journal of Molecular Sciences (2022).